Zenith National Insurance Corp. and Subsidiaries

Consolidated Financial Statements as of September 30, 2022 and December 31, 2021 and for the three and nine months ended September 30, 2022 and 2021 (unaudited)

Zenith National Insurance Corp. and Subsidiaries Consolidated Financial Statements (unaudited)

Table of Contents

| | <u>Page</u> |
|---|-------------|
| Consolidated Balance Sheets – September 30, 2022 and December 31, 2021 | 3 |
| Consolidated Statements of Comprehensive Income – Three and Nine Months Ended September 30, 2022 and 2021 | 4 |
| Consolidated Statements of Cash Flows – Nine Months Ended September 30, 2022 and 2021 | 5 |
| Consolidated Statements of Stockholders' Equity – Nine Months Ended September 30, 2022 and 2021 | 7 |
| Notes to Consolidated Financial Statements | 8 |

ZENITH NATIONAL INSURANCE CORP. AND SUBSIDIARIES CONSOLIDATED BALANCE SHEETS (UNAUDITED)

| | | September 30, | | December 37 |
|--|----|-----------------|----|----------------|
| (In thousands, except par value) | | 2022 | | 2021 |
| Assets: | | | | |
| Investments: | | | | |
| Fixed maturity securities, at fair value (amortized cost \$1,027,830 in 2022 and | | | | |
| \$898,491 in 2021) | \$ | 1,000,727 | \$ | 897,537 |
| Equity securities, at fair value (cost \$324,938 in 2022 and \$261,116 in 2021) | | 403,574 | | 348,776 |
| Short-term investments, at fair value which approximates cost | | 3,996 | | 188,687 |
| Mortgage loans, at fair value which approximates cost | | 163,663 | | 79,337 |
| Other investments | | 161,419 | | 155,664 |
| Derivative assets, at fair value (cost \$14,058 in 2022 and \$13,225 in 2021) | | 5,193 | | 3,214 |
| Total investments | | 1,738,572 | | 1,673,215 |
| Cash | | 49,013 | | 104,568 |
| Accrued investment income | | 7,381 | | 4,466 |
| Premiums receivable | | 56,390 | | 48,816 |
| Earned but unbilled premium receivable | | 4,002 | | |
| Reinsurance recoverables | | 49,637 | | 47,854 |
| Deferred policy acquisition costs | | 21,931 | | 17,543 |
| Deferred tax asset | | 54,312 | | 44,19 <i>1</i> |
| Operating lease right-of-use assets | | 23,374 | | 25,107 |
| Goodwill | | 20,985 | | 20,985 |
| Other assets | | 56,978 | | 59,161 |
| Total assets | \$ | 2,082,575 | \$ | 2,045,906 |
| Liebilities | | | | |
| Liabilities: | ¢ | 1 055 644 | ሰ | 1 040 076 |
| Unpaid losses and loss adjustment expenses | \$ | 1,055,644 | \$ | 1,049,076 |
| Unearned premiums | | 128,587 | | 105,236 |
| Policyholders' dividends accrued | | 32,582 | | 30,780 |
| Long-term debt Income tax payable | | 38,333 1,279 | | 38,310 649 |
| Operating lease liabilities | | 25,041 | | 26,622 |
| Derivative liabilities | | 23,041 | | 20,022 |
| Other liabilities | | 94,386 | | 89,757 |
| Total liabilities | | 1,375,852 | | 1,340,810 |
| | | 1,010,002 | | 1,040,010 |
| Commitments and contingencies (see Note 10) | | | | |
| Stockholders' equity: | | | | |
| Common stock, \$1 par value, 40 authorized shares; 39 shares issued and | | | | |
| outstanding | | 39 | | 39 |
| Additional paid-in capital | | 395,999 | | 399,159 |
| Retained earnings | | 320,989 | | 314,948 |

| Retained earnings | 320,989 | 314,948 |
|--|--------------|-----------------|
| Accumulated other comprehensive loss | (10,304) | (9,050) |
| Total stockholders' equity | 706,723 | 705,096 |
| Total liabilities and stockholders' equity | \$ 2,082,575 | \$ 2,045,906 |
| | | |

ZENITH NATIONAL INSURANCE CORP. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED)

| | Ended 30, | | | hs Ended ber 30, | | | |
|---|--------------|---------|----|---------------------|---------------|----|----------|
| (In thousands) | | 2022 | | 2021 | 2022 | | 2021 |
| Revenues: | | | | | | | |
| Net premiums earned | \$ | 190,285 | \$ | 184,844 | \$ 542,537 | \$ | 527,323 |
| Net investment income | | 6,494 | | 2,090 | 16,242 | | 14,730 |
| Net realized gain (loss) on investments | | (4,797) | | 21,027 | (3,890) | | 45,757 |
| Change in net unrealized gains/losses on fair | | | | | | | |
| value option investments | | 47,944 | | (454) | (35,682) | | 78,325 |
| Net gains (losses) on derivatives | | 6,140 | | (1,877) | 6,445 | | 16,552 |
| Service fee income | | 2,158 | | 1,543 | 5,618 | | 4,357 |
| Total revenues | | 248,224 | | 207,173 | 531,270 | | 687,044 |
| Expenses: | | | | | | | |
| Losses and loss adjustment expenses | | | | | | | |
| incurred | | 105,008 | | 101,294 | 297,815 | | 277,104 |
| Underwriting and other operating expenses: | | , | | , | _0.,0.0 | | , |
| Policyholder acquisition costs | | 38,422 | | 35,178 | 110,896 | | 100,993 |
| Underwriting and other costs | | 33,641 | | 31,196 | 98,266 | | 93,147 |
| Policyholders' dividends | | 4,484 | | 4,631 | 13,896 | | 14,422 |
| Interest expense | | 830 | | 830 | 2,490 | | 2,490 |
| Total expenses | | 182,385 | | 173,129 | 523,363 | | 488,156 |
| Income before tax | | 65,839 | | 34,044 | 7,907 | | 198,888 |
| Income tax expense | | 13,958 | | 6,266 | 1,866 | | 40,605 |
| Decrease in valuation allowance | | -, | | -, | , | | (29,500) |
| Net income | \$ | 51,881 | \$ | 27,778 | \$ 6,041 | \$ | 187,783 |
| Change in unrealized gains/losses on | T | - , | r | , - | - , | T | - , , |
| investments, net of tax | | 159 | | (412) | (377) | | 1,309 |
| Change in unrealized foreign currency | | | | 、 -/ | (- · / | | , |
| translation adjustments, net of tax | | (1,479) | | (200) | (877) | | (2,249) |
| Other comprehensive loss | | (1,320) | | (612) | (1,254) | | (940) |
| Total comprehensive income | \$ | 50,561 | \$ | 27,166 | \$ 4,787 | \$ | 186,843 |

ZENITH NATIONAL INSURANCE CORP. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)

| | 1 | Nine Months Ended S | | | | |
|--|----|---------------------|-----------------|--|--|--|
| (In thousands) | | 2022 | 2021 | | | |
| Cash flows from operating activities: | | | | | | |
| Premiums collected | \$ | 570,193 \$ | 531,569 | | | |
| Investment income received | Ψ | 14,917 | 26,951 | | | |
| Losses and loss adjustment expenses paid | | (293,656) | (276,508) | | | |
| Underwriting and other operating expenses paid | | (222,226) | (207,062) | | | |
| Interest paid | | (3,292) | (3,292) | | | |
| Income taxes paid | | (11,028) | (16,651) | | | |
| Net cash provided by operating activities | | 54,908 | 55,007 | | | |
| Cash flows from investing activities: | | | | | | |
| Purchases of investments: | | | | | | |
| Fixed maturity securities – fair value option | | (1,058,622) | (889,373) | | | |
| Equity securities – fair value option | | (54,128) | (5,000) | | | |
| Mortgage loans | | (85,939) | (28,005) | | | |
| Derivatives | | (4,125) | (134) | | | |
| Corporate Ioan - affiliate | | (5,000) | | | | |
| Other investments | | (8,726) | (5,850) | | | |
| Proceeds from maturities and redemptions of investments: | | | | | | |
| Fixed maturity securities – fair value option | | 278,861 | 842,126 | | | |
| Proceeds from sales of investments: | | | | | | |
| Fixed maturity securities – fair value option | | 640,444 | 12,484 | | | |
| Equity securities – fair value option | | 4,902 | | | | |
| Derivatives | | 64 | | | | |
| Mortgage loans | | 2,042 | 10,000 | | | |
| Other investments | | 4,082 | 5,140 | | | |
| Net decrease in short-term investments | | 182,640 | 3,289 | | | |
| Net derivative cash settlements | | 4,679 | 9,851 | | | |
| Capital expenditures and other | | (2,324) | (1,163) | | | |
| Net cash used in investing activities | | (101,150) | (46,635) | | | |
| Cash flows from financing activities: | | | | | | |
| Purchase of Fairfax shares for restricted stock awards | | (9,313) | (4,750) | | | |
| Net cash used in financing activities | | (9,313) | (4,750) | | | |
| Natingraada (daaraada) in adah | | | 3,622 | | | |
| Net increase (decrease) in cash | | (55,555) | 5,622 62,838 | | | |
| Cash at beginning of period | Φ. | 104,568 | , | | | |
| Cash at end of period | \$ | 49,013 \$ | 66,460 | | | |

ZENITH NATIONAL INSURANCE CORP. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF CASH FLOWS (CONTINUED) (UNAUDITED)

| | N | Nine Months Ended Septem | | | | | |
|--|----|--------------------------|----|----------|--|--|--|
| (In thousands) | | 2022 | | 2021 | | | |
| Reconciliation of net income to net cash provided by operating activities: | | | | | | | |
| Net income | \$ | 6,041 | \$ | 187,783 | | | |
| Adjustments to reconcile net income to net cash provided by operating activities: | | | | | | | |
| Depreciation expense | | 1,486 | | 1,947 | | | |
| Net amortization expense | | 1,612 | | 7,659 | | | |
| Net realized losses (gains) on investments | | 3,890 | | (45,757) | | | |
| Change in net unrealized losses/gains on fair value option investments | | 35,682 | | (78,325) | | | |
| Net gains on derivatives | | (6,445) | | (16,552) | | | |
| Equity in losses of investee | | 284 | | 1,872 | | | |
| Stock-based compensation expense | | 6,153 | | 3,988 | | | |
| Decrease (increase) in: | | | | | | | |
| Accrued investment income | | (2,915) | | 3,526 | | | |
| Premiums receivable | | (13,602) | | (36,992) | | | |
| Reinsurance recoverables | | (1,783) | | (7,982) | | | |
| Deferred policy acquisition costs | | (4,388) | | (5,300) | | | |
| Net income taxes | | (9,161) | | (5,546) | | | |
| Increase (decrease) in: | | | | | | | |
| Unpaid losses and loss adjustment expenses | | 6,568 | | 8,256 | | | |
| Unearned premiums | | 23,351 | | 26,548 | | | |
| Policyholders' dividends accrued | | 1,802 | | 1,016 | | | |
| Accrued expenses | | 3,388 | | 4,840 | | | |
| Interest payable | | (823) | | (823) | | | |
| Prepaid policy and guarantee fund assessments | | 5,127 | | 4,974 | | | |
| Other | | (1,359) | | (125) | | | |
| Net cash provided by operating activities | \$ | 54,908 | \$ | 55,007 | | | |

ZENITH NATIONAL INSURANCE CORP. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (UNAUDITED)

| | N | ine Months Ended S | eptember 30, | |
|--|----|--------------------|--------------|--|
| (In thousands) | | 2022 | 2021 | |
| Common stock: | \$ | 39 \$ | 39 | |
| Additional paid-in capital: | | | | |
| Beginning of period | | 399,159 | 400,264 | |
| Stock-based compensation expense | | 6,153 | 3,988 | |
| Purchases of Fairfax shares for restricted stock awards | | (9,313) | (4,750) | |
| End of period | | 395,999 | 399,502 | |
| Retained earnings: | | | | |
| Beginning of period | | 314,948 | 118,659 | |
| Net income | | 6,041 | 187,783 | |
| End of period | | 320,989 | 306,442 | |
| Accumulated other comprehensive loss: | | | | |
| Beginning of period | | (9,050) | (6,687) | |
| Change in unrealized gains/losses on investments, net of tax | | (377) | 1,309 | |
| Change in unrealized foreign currency translation adjustments, | | | | |
| net of tax | | (877) | (2,249) | |
| End of period | | (10,304) | (7,627) | |
| Total stockholders' equity | \$ | 706,723 \$ | 698,356 | |

Note 1. Basis of Presentation and Accounting Policies

Basis of Presentation

Zenith National Insurance Corp. ("Zenith National") is a Delaware holding company, which is a wholly-owned indirect subsidiary of Fairfax Financial Holdings Limited ("Fairfax"). Fairfax is a Canadian financial services holding company, whose common stock is publicly traded on the Toronto Stock Exchange ("TSX"), and is principally engaged in property and casualty insurance, reinsurance and associated investment management. Zenith National's wholly-owned subsidiaries (primarily Zenith Insurance Company ("Zenith Insurance")), specialize in the workers' compensation insurance business, nationally and, since 2010, in the property-casualty business for California agriculture. Unless otherwise indicated, all references to the "Company" refer to Zenith National together with its subsidiaries.

The accompanying unaudited Consolidated Financial Statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America ("GAAP") for interim financial information. Accordingly, they do not include all of the information and notes required by GAAP for complete financial statements. In the opinion of management, all adjustments (including normal, recurring adjustments) necessary for a fair presentation of the Company's financial position and results of operations for the periods presented have been included. The results of operations for an interim period are not necessarily indicative of the results for an entire year. For further information, refer to the Audited Consolidated Financial Statements and Notes thereto of the Company for the year ended December 31, 2021.

The accompanying Consolidated Financial Statements differ from the financial information published by Fairfax in regards to the Company primarily due to differences between GAAP and International Financial Reporting Standards ("IFRS," the reporting basis used by Fairfax), intercompany investment transactions and accounting adjustments recorded by Fairfax related to the acquisition of the Company.

Recent Accounting Standards Not Yet Adopted

Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions

In June 2022, the FASB issued new guidance which clarifies the existing fair value measurement guidance, when measuring the fair value of an equity security subject to contractual restrictions that prohibit the sale of an equity security and introduces new disclosure requirements for equity securities subject to contractual sale restrictions that are measured at fair value. The new standard clarifies that a contractual restriction on the sale of an equity security should not be considered in measuring the fair value of the security and requires an entity holding equity securities with contractual sale restrictions to disclose the fair value of equity securities subject to contractual sale restrictions, the nature and remaining duration of the restrictions and the circumstances that could cause a lapse in the restrictions. The guidance is effective for annual periods beginning after December 15, 2023, and interim periods within those annual periods. Early adoption is permitted. The guidance is not expected to have a material impact on the Company's consolidated financial position, results of operations or cash flows.

Subsequent Events

The Company evaluated subsequent events through the date and time that the Consolidated Financial Statements were issued on November 10, 2022.

Note 2. Investments

The cost or amortized cost and fair value of investments recorded at fair value under the fair value option as of September 30, 2022 and December 31, 2021 were as follows:

| | | Cost or | • | | | |
|---|-----------|-----------|---------------|------------------|----------|-----------------|
| | Amortized | | - | Gross Unrealized | | Fair |
| (In thousands) | | Cost | Gains | | (Losses) | Value |
| September 30, 2022 | | | | | | |
| Fair value option investments: | | | | | | |
| Fixed maturity securities: | | | | | | |
| U.S. Government debt | \$ | 988,286 | \$ 347 | \$ | (25,081) | \$ 963,552 |
| State and local government debt | | 5,064 | 5 | | | 5,069 |
| Foreign government debt | | 15,823 | | | (1,163) | 14,660 |
| Corporate debt | | 18,657 | | | (1,211) | 17,446 |
| Total fixed maturity securities | | 1,027,830 | 352 | | (27,455) | 1,000,727 |
| Equity securities | | 324,938 | 127,811 | | (49,175) | 403,574 |
| Short-term investments | | 3,999 | | | (3) | 3,996 |
| Mortgage loans | | 163,663 | | | | 163,663 |
| Other investments – cost-method partnerships | | 35,150 | 9,161 | | (2,250) | 42,061 |
| Other investments – affiliate corporate loans | | 14,322 | | | (134) | 14,188 |
| Other investments – contingent consideration | | | | | | |
| receivable | | 14,936 | 2,055 | | | 16,991 |
| Total fair value option investments | \$ | 1,584,838 | \$ 139,379 | \$ | (79,017) | \$ 1,645,200 |
| December 31, 2021 | | | | | | |
| Fair value option investments: | | | | | | |
| Fixed maturity securities: | | | | | | |
| U.S. Government debt | \$ | 859,495 | | \$ | (459) | \$ 859,036 |
| State and local government debt | | 10,179 | \$ 321 | | () | 10,500 |
| Foreign government debt | | 15,014 | | | (1,416) | 13,598 |
| Corporate debt | | 13,803 | 600 | | | 14,403 |
| Total fixed maturity securities | | 898,491 | 921 | | (1,875) | 897,537 |
| Equity securities | | 261,116 | 113,129 | | (25,469) | 348,776 |
| Short-term investments | | 188,689 | - | | (2) | 188,687 |
| Mortgage loans | | 79,337 | | | . , | 79,337 |
| Other investments – cost-method partnerships | | 35,790 | 9,195 | | (2,387) | 42,598 |
| Other investments – affiliate corporate loans | | 9,322 | 887 | | | 10,209 |
| Other investments – contingent consideration | | , | | | | , |
| receivable | | 17,038 | 1,645 | | | 18,683 |
| Total fair value option investments | \$ | 1,489,783 | \$ 125,777 | \$ | (29,733) | \$ 1,585,827 |

Fixed maturity securities, including short-term investments, by contractual maturity as of September 30, 2022 were as follows:

| | | Amortized Cost | | | | |
|--|----|-------------------|----|-----------|--|--|
| (In thousands) | | | | | | |
| Due in one year or less | \$ | 83,365 | \$ | 82,508 | | |
| Due after one year through five years | | 936,859 | | 911,369 | | |
| Due after five years through ten years | | 8,807 | | 8,797 | | |
| Due after ten years | | 2,798 | | 2,049 | | |
| Total | \$ | 1,031,829 | \$ | 1,004,723 | | |

Expected maturities may differ from contractual maturities because borrowers may have the right to call or prepay obligations with or without call or prepayment penalties.

As of September 30, 2022 and December 31, 2021, total investments also included other investments detailed below and derivative contracts described in Note 3.

Other investments consisted of the following:

| (In thousands) | September 30, 2022 | December 31, 2021 |
|--|-----------------------|----------------------|
| Equity-method common stock (a) | \$ 88,179 | \$ 84,174 |
| Cost-method partnerships, at fair value (cost \$35,150 in 2022 and \$35,790 in 2021) (b) | 42,061 | 42,598 |
| Affiliate corporate loans, at fair value (amortized cost \$14,322 in 2022 and \$9,322 in 2021) | 14,188 | 10,209 |
| Contingent consideration receivable, at fair value (cost \$14,936 in 2022 and \$17,038 in 2021) | 16,991 | 18,683 |
| Total other investments | \$ 161,419 | \$ 155,664 |

(a) Investments in common stock accounted for under the equity-method are recorded at cost, adjusted for subsequent purchases, distributions, other-than-temporary impairments, if any, and the Company's share of the changes in the investee's net asset value ("NAV") since the initial acquisition.

(b) Partnerships and limited liability company investments where the Company's ownership is minor, and the Company does not have significant operating or financial influence are recorded at fair value.

As of September 30, 2022, the Company had commitments to invest an additional \$9.9 million in partnerships and limited liability companies.

Net realized gains (losses) on investments, excluding derivatives, were as follows:

| | Three Months Ended September 30, | | | | | | ns Ended ber 30, | |
|--|-------------------------------------|---------|----|--------|----|---------|-------------------------|--|
| (In thousands) | | 2022 | | 2021 | | 2022 | 2021 | |
| Sales of fixed maturity securities, including short-term | | | | | | | | |
| investments and other (a) | \$ | (3,193) | \$ | 51 | \$ | (3,366) | \$ (9,291) | |
| Sale of equity securities (b) | | | | | | (1,578) | | |
| Sale of mortgage loans | | | | 112 | | | 112 | |
| Gains (losses) from other investments (c) | | (1,604) | | 20,864 | | 1,054 | 54,936 | |
| Net realized gains (losses) on investments | \$ | (4,797) | \$ | 21,027 | \$ | (3,890) | \$ 45,757 | |

(a) Net realized losses on sales of fixed maturity securities, including short-term investments and other in the three months ended September 30, 2022 primarily included a realized loss on sale of U.S. government securities of \$2.9 million.

Net realized losses on sales of fixed maturity securities, including short-term investments and other in the nine months ended September 30, 2022 primarily included \$5.8 million of indemnity-related losses recorded in connection with Atlas Corp.'s ("Atlas") acquisition of Apple Bidco Limited ("AB"), both affiliates of the Company; a realized loss on sale of U.S. government securities of \$3.3 million, partially offset by a realized gain of \$5.5 million on the conversion of fair value option fixed maturity securities into common stock.

Net realized losses on sales of fixed maturity securities, including short-term investments and other in the nine months ended September 30, 2021 primarily included \$10.9 million of indemnity-related losses recorded in connection with Atlas' acquisition of AB.

- (b) Net realized losses on sales of equity securities in the nine months ended September 30, 2022, included realized losses of \$3.0 million on the sale of three fair value option common stocks, partially offset by a realized gain of \$1.4 million related to the redemption of a preferred stock investment in exchange for common stock.
- (c) Net realized losses from other investments in the three months ended September 30, 2022 included an other-than-temporary impairment of \$1.7 million for the Company's equity-method investment in Farmers Edge Inc. ("FE").

Net realized gains from other investments in the nine months ended September 30, 2022, included realized gains of \$2.3 million from cost-method partnership distributions, partially offset by an other-than-temporary impairment of \$1.3 million for the Company's equity-method investment in FE.

Net realized gains from other investments in the three and nine months ended September 30, 2021 primarily included a realized gain of \$20.1 million for the sale of the Company's equity-method investment in Toys "R" Us Canada in August 2021, dilution gains on equity-method investments of \$19.7 million for Boat Rocker Media Inc. ("Boat Rocker") and \$10.6 million for FE, in connection with their respective IPOs, and a \$0.8 million realized gain on conversion of FE affiliate loans. See Note 5.

The changes in unrealized gains/losses on investments recorded as a separate component of stockholders' equity were as follows:

| Three Months Ended September 30, | | | | Nine Months End September 30, | | | | |
|---|----|-----------|----|----------------------------------|----|-------|----|-------|
| (In thousands) | | 2022 2021 | | | | 2022 | | 2021 |
| Change in unrealized gains/losses on investments, | | | | | | | | |
| before tax | \$ | 202 | \$ | (521) | \$ | (476) | \$ | 1,657 |
| After tax | \$ | 159 | \$ | (412) | \$ | (377) | \$ | 1,309 |

The changes in net unrealized gains/losses on fair value option investments still held were as follows:

| | Three M Sept | lonths ember | | Nine Mo Septe | |
|--|-----------------|-----------------|-------|------------------|--------------|
| (In thousands) | 2022 | | 2021 | 2022 | 2021 |
| Change in net unrealized gains/losses recognized on fair value option investments Less: Net losses (gains) recognized on fair value | \$ 47,944 | \$ | (454) | \$ (35,682) | \$ 78,325 |
| option investments sold | 113 | | (3) | 1,214 | (3,710) |
| Change in net unrealized gains/losses recognized on fair value option investments still held at the reporting date | \$ 47,831 | \$ | (451) | \$ (36,896) | \$ 82,035 |

Net investment income was as follows:

| | Three M Sept | lonths ember | | | lonths tembe | Ended r 30, |
|--|-----------------|-----------------|-------|--------------|-----------------|----------------|
| (In thousands) | 2022 | | 2021 | 2022 | | 2021 |
| Fixed maturity securities (a) | \$ 5,103 | \$ | 1,370 | \$ 10,606 | \$ | 6,484 |
| Equity securities (b) | 1,433 | | 1,047 | 4,493 | | 12,118 |
| Mortgage loans | 2,882 | | 561 | 5,842 | | 1,281 |
| Derivatives | | | (16) | | | 1,474 |
| Short-term and other investments (a) | 415 | | 183 | 1,153 | | 828 |
| Income (loss) from equity-method investments (c) | (1,477) | | 858 | (284) | | (1,872) |
| Subtotal | 8,356 | | 4,003 | 21,810 | | 20,313 |
| Investment expenses | 1,862 | | 1,913 | 5,568 | | 5,583 |
| Net investment income | \$ 6,494 | \$ | 2,090 | \$ 16,242 | \$ | 14,730 |

(a) Income from fixed maturity securities in the three and nine months ended September 30, 2022 increased compared to the corresponding period of 2021, primarily due to the sales and maturities of short-dated U.S. Treasury securities and corporate bonds, with the proceeds reinvested in mortgage loans and higher yielding long-term U.S. Treasury securities in response to rising interest rates.

(b) Income from equity securities in the nine months ended September 30, 2021, included a \$8.3 million special dividend received from Resolute Forest Products in June 2021.

(c) Income (loss) from equity-method investments for each period presented is detailed below:

| | | Three M Septe | onths embe | | Nine M Sept | onths embe | |
|--|----|-------------------|---------------|---------|----------------|---------------|---------|
| (In thousands) | _ | 2022 | | 2021 | 2022 | | 2021 |
| Astarta Holdings NV | | | | | \$ 4,829 | \$ | 571 |
| Exco Resources Inc. | \$ | 1,119 | \$ | (449) | 1,119 | | (562) |
| Helios Fairfax Partners Corp. | | (1,553) | | 3 | (1,731) | | (1,811) |
| Farmers Edge Inc. | | (641) | | (301) | (1,721) | | (1,482) |
| Fairfax India Holdings Corp. | | (708) | | 2,128 | (1,317) | | 5,314 |
| Boat Rocker Media Inc. | | `156 [´] | | (1,038) | (1,224) | | (4,839) |
| Alberta ULC | | (496) | | 297 | (1,068) | | 610 |
| Other | | 646 [´] | | 218 | 829 | | 327 |
| Income (loss) from equity-method investments | \$ | (1,477) | \$ | 858 | \$ (284) | \$ | (1,872) |

As of September 30, 2022 and December 31, 2021, investments with a fair value of \$795 million and \$850 million, respectively, were on deposit with regulatory authorities in compliance with insurance company regulations. As of September 30, 2022, the Company had additional qualifying securities with a fair value of \$173 million available for deposit.

Note 3. Derivative Contracts

Derivatives entered into by the Company are considered investments or economic hedges and are not designated for hedge accounting treatment for financial reporting. Derivatives are carried at fair value. The fair value of derivatives in a gain position and fair value of derivatives in a loss position are presented as derivative assets and derivative liabilities, respectively, in the Consolidated Balance Sheets. The initial premium paid for a derivative contract, if any, is recorded as a derivative asset and subsequently adjusted for changes in the fair value of the contract at each reporting date. Changes in the fair value of derivatives are recorded as net gains (losses) on derivatives in the Consolidated Statements of Comprehensive Income (Loss), with a corresponding adjustment to the carrying value of the derivative asset or liability. Cash settlements related to fair value changes on derivatives are also recorded in the Consolidated Statements of Comprehensive Income (Loss) as net gains (losses) on derivatives and are recorded as an investing activity in the Consolidated Statements of Cash Flows.

Cash received from counterparties as collateral for derivative contracts is recorded as other assets with a corresponding liability recorded in other liabilities in the Consolidated Balance Sheets. Securities pledged by counterparties to the Company as collateral for derivatives in a gain position are not recorded as assets. Securities pledged by the Company as collateral to counterparties for derivative contracts in a loss position, as well as contractually required independent collateral, are recorded in assets pledged for derivative obligations in the Consolidated Balance Sheets.

The following table summarizes the notional amounts, cost and fair values of derivative contracts:

| | Notional | | Fair Val | ue of | Derivative |
|---------------------------|-----------------|--------------|-------------|-------|-------------|
| (In thousands) | Amount | Cost | Assets | | Liabilities |
| September 30, 2022 | | | | | |
| CPI-linked derivatives | \$ 3,558,178 | \$ 13,091 | \$ 11 | | |
| Foreign exchange forwards | 88,352 | | 1,768 | | |
| Equity warrants (a) | 13,527 | 967 | 3,414 | | |
| Total | | \$ 14,058 | \$ 5,193 | | |
| December 31, 2021 | | | | | |
| CPI-linked derivatives | \$ 3,548,602 | \$ 13,091 | \$ 25 | | |
| Foreign exchange forwards | 81,067 | | | \$ | 380 |
| Equity warrants (b) | 8,527 | 134 | 3,189 | | |
| Total | | \$ 13,225 | \$ 3,214 | \$ | 380 |

(a) As of September 30, 2022, equity warrants included 0.7 million shares and 0.2 million shares of Atlas common stock warrants and Kennedy Wilson common stock warrants, respectively.

(b) As of December 31, 2021, equity warrants included 0.7 million shares of Atlas common stock warrants.

The gains (losses) from settlements and changes in fair value of the derivative contracts were recorded in net gains (losses) on derivatives in the Consolidated Statements of Comprehensive Income (Loss) and were as follows:

| | Three Mont Septem | | Nine Months Septembe | |
|--|----------------------|--------------|-------------------------|---------|
| (In thousands) | 2022 | 2021 | 2022 | 2021 |
| Gains (losses) on settlements | | | | |
| Equity derivatives: | | | | |
| Equity total return swaps – long positions | \$ | 6 (3,381) | \$ | 11,219 |
| Equity warrants | \$ 1 | \$ | 240 | |
| CPI-linked derivatives (a) | | (5,354) | | (9,419) |
| Foreign exchange forwards | 2,981 | 3,903 | 4,679 | (1,502) |
| Total | 2,982 | (4,832) | 4,919 | 298 |
| Change in fair value | | | | |
| Equity derivatives: | | | | |
| Equity total return swaps – long positions | | (670) | | 1,607 |
| Equity warrants | 1,029 | 333 | (608) | 3,677 |
| CPI-linked derivatives (a) | (20) | 5,343 | (14) | 9,191 |
| Foreign exchange forwards | 2,149 | (2,051) | 2,148 | 1,779 |
| Total | 3,158 | 2,955 | 1,526 | 16,254 |
| Net gains (losses) on derivatives | | | | |
| Equity derivatives: | | | | |
| Equity total return swaps – long positions | | (4,051) | | 12,826 |
| Equity warrants | 1,030 | 333 | (368) | 3,677 |
| CPI-linked derivatives (a) | (20) | (11) | (14) | (228) |
| Foreign exchange forwards | 5,130 | 1,852 | 6,827 | 277 |
| Total net gains (losses) on derivatives | \$ 6,140 \$ | 6 (1,877) \$ | 6,445 \$ | 16,552 |

(a) Two CPI-linked derivative contracts with the notional amount of \$0.9 billion, matured in the nine months ended September 30, 2021, with the fair value of zero at maturity and \$9.4 million of losses previously recognized in the change in fair value component of net gains (losses) on derivatives were reclassified to gains (losses) on settlements.

Equity contracts

The Company held long equity total return swaps on individual equities and equity index put options for investment purposes. These contracts provided the total return on a notional amount (including dividends and capital gains or losses) that is directly correlated to changes in fair value of the underlying individual equities or equity indexes in exchange for the payment of a floating rate of interest on the notional amount. Total return swaps required no initial net cash investment; and at inception the fair value was zero. The Company's long equity total return swaps may have contained reset provisions requiring counterparties to cash-settle on a monthly or quarterly basis for any fair value changes arising subsequent to the most recent reset date. Any cash amounts paid to settle unfavorable fair value changes and conversely, any cash amounts received in settlement of favorable fair value changes, were recorded as net gains (losses) on derivatives in the Consolidated Statements of Comprehensive Income (Loss) (included in the gains on settlements section in the table above).

As of December 31, 2021, the Company closed all its total return swap positions.

CPI-linked derivative contracts

The Company has purchased derivative contracts referenced to consumer price indexes ("CPI") in the United States and Europe to serve as an economic hedge against the potential adverse financial impact on the Company of decreasing price levels. In the event of a sale, maturity or early settlement of any of these contracts, the Company would receive the fair value of that contract on the date of the transaction. The Company's maximum potential loss on any contract is limited to the original cost of that contract. Net unrealized gains (losses) on CPI-linked derivative contracts typically reflect the market's expectation of decreases (increases) in the values of the CPI indexes underlying these contracts at their respective maturities during the periods presented (these contracts are structured to benefit the Company during periods of decreasing CPI index values). As of September 30, 2022, these contracts had a remaining weighted average life of approximately 1.6 years.

The following table summarizes the notional amounts and underlying CPI Index price ("strike price") for the Company's CPI-linked derivative contracts at initiation and the index value as of September 30, 2022 and December 31, 2021:

| | Nation | | | Weighted Average | |
|---|-----------|--------|------------|-----------------------------|--------|
| | Original | iai Ai | mount | Strike Price In Original | Index |
| (Notional amount in thousands) | Currency | | US Dollars | Currency | Value |
| Underlying CPI Index: September 30, 2022 | · | | | · | |
| United States | 2,980,000 | \$ | 2,980,000 | 235.47 | 296.81 |
| European Union | 500,000 | | 578,178 | 100.63 | 119.00 |
| | | \$ | 3,558,178 | | |
| December 31, 2021 | | | | | |
| United States | 2,980,000 | \$ | 2,980,000 | 235.47 | 278.80 |
| European Union | 500,000 | | 568,602 | 100.63 | 109.97 |
| - · | | \$ | 3,548,602 | | |

Foreign exchange forward contracts

The Company has exposure to foreign currency fluctuations for foreign investments held. Foreign exchange forward contracts ("foreign exchange forwards"), primarily denominated in the Canadian dollar are used to manage certain foreign currency exposures arising from foreign currency denominated investments. These foreign exchange forwards require no initial net cash investment and at inception the fair value is zero. These contracts have a term to maturity of less than one year and may be renewed at market rates.

Counterparty collateral and exposure

The Company limits counterparty risk through the terms of master netting agreements negotiated with counterparties to its derivative contracts. These agreements provide for a single net settlement of all financial instruments covered by the agreement in the event of default by the counterparty, thereby permitting obligations owed by the Company to a counterparty to be offset to the extent of the aggregate amount receivable by the Company from that counterparty ("net settlement arrangements"). Pursuant to these agreements, the counterparties to the derivative contracts are also contractually required to deposit eligible collateral in collateral accounts (subject to certain minimum thresholds) for the benefit of the Company depending on the then current fair value of the derivative contracts.

The following table sets out the Company's exposure to credit risk related to the counterparties to its derivative contracts:

| | S | eptember 30, | December 31, |
|--|----|--------------|--------------|
| (In thousands) | | 2022 | 2021 |
| Total derivative assets (a) | \$ | 1,779 | \$ 25 |
| Fair value of collateral deposited for the benefit of the Company | | | (1) |
| Net derivative counterparty exposure after net settlement and collateral | | | |
| arrangements | \$ | 1,779 | \$ 24 |

(a) Excludes equity warrants with a fair value of \$3.4 million and \$3.2 million as of September 30, 2022 and December 31, 2021, respectively, which are not subject to counterparty risk.

The net derivative counterparty exposure after net settlement and collateral arrangements relates principally to the timing of collateral placement.

As of September 30, 2022, no amounts were pledged by counterparties for the Company's benefit. As of December 31, 2021, the counterparties pledged \$0.3 million in cash for the Company's benefit. The Company recorded the cash collateral as other assets and recorded a corresponding liability in its Consolidated Balance Sheets. The Company does not record in its Consolidated Balance Sheets securities pledged by counterparties as collateral for derivatives in a gain position.

As of September 30, 2022 and December 31, 2021, the Company had no pledged amounts recorded as contractually required collateral to a counterparty on any derivative contracts.

Offsetting of Derivative Assets/Liabilities

The Company entered into master netting agreements with certain of its derivative counterparties whereby the collateral provided (held) is calculated on a net basis. In accordance with GAAP, the Company elected not to offset derivative assets and liabilities in the Consolidated Balance Sheets for the counterparties with the master netting agreement. The following table summarizes by counterparty (1) the gross and net amounts reflected as derivative assets (excluding equity warrants) and liabilities in the Consolidated Balance Sheets; (2) the gross amounts of the derivative instruments eligible for netting but not offset in the Consolidated Balance Sheets; and (3) financial collateral received and pledged which is contractually permitted to be offset upon an event of default, but is not allowed to be presented net under GAAP (net amount of exposure).

| | Gross and net | | Gross amounts not offset in the Consolidated Balance Sheets | | | | | | | |
|------------------------------|-----------------------------|-------------------|--|------------------------|----|-----------|--|--|--|--|
| | amounts reflected in the | | | Collateral provided | | Net | | | | |
| | Consolidated | Derivative | (h | eld) - financial | | amount of | | | | |
| (In thousands) | Balance Sheets | asset (liability) | in | struments (a) | | exposure | | | | |
| September 30, 2022 | | | | | | | | | | |
| Derivative assets: | | | | | | | | | | |
| Bank of New York Mellon (b) | \$ 1,768 | | | | \$ | 1,768 | | | | |
| Citibank, N.A. | 11 | | | | | 11 | | | | |
| Total derivative assets (c) | \$ 1,779 | | | | \$ | 1,779 | | | | |
| December 31, 2021 | | | | | | | | | | |
| Derivative assets: | | | | | | | | | | |
| Citibank, N.A. | \$ 24 | | | | \$ | 24 | | | | |
| Deutsche Bank AG London | 1 | | \$ | (1) | | | | | | |
| Total derivative assets (c) | \$ 25 | | \$ | (1) | \$ | 24 | | | | |
| Derivative liabilities: | | | | | | | | | | |
| Bank of New York Mellon (b) | \$ (380) | | | | \$ | (380) | | | | |
| Total derivative liabilities | \$ (380) | | | | \$ | (380) | | | | |

(a) Amounts of collateral pledged to the Company by the counterparties (collateral held) and pledged by the Company to the counterparties (collateral provided) reflected above are to the extent of the net counterparty exposure before collateral.

(b) Represents foreign currency contracts that are not subject to a master netting arrangement.
(c) Excludes equity warrants with a fair value of \$3.4 million and \$3.2 million as of September 30, 2022 and December 31, 2021, respectively, which are not subject to counterparty risk.

Note 4. Fair Value Measurements

Fair values for substantially all of the Company's financial instruments are measured using market or income approaches. Considerable judgment may be required in interpreting market data used to develop estimates of fair value. Accordingly, actual values realized in future market transactions may differ from the estimates presented in these consolidated financial statements. In determining fair value, the Company primarily uses prices and other relevant information generated by market transactions involving identical or comparable assets ("market approach"). The Company also considers the impact of a significant decrease in volume and level of activity for an asset or liability when compared with normal activity to identify transactions that are not orderly.

Fair value measurements are determined under a three level hierarchy that prioritizes the inputs to valuation techniques used to measure fair value, distinguishing between market participant assumptions developed based on market data obtained from sources independent of the reporting entity ("observable inputs") and the reporting entity's own assumptions about market participant assumptions developed based on the best information available in the circumstances ("unobservable inputs"). The hierarchy level assigned to each security carried at fair value is based on the Company's assessment of the transparency and reliability of the inputs used in the valuation of each instrument at the measurement date. The highest priority is given to unadjusted quoted prices in active markets for identical assets (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). Securities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company recognizes transfers between levels at the end of each reporting period in which the transfer is identified.

The three hierarchy levels are defined as follows:

Level 1— Inputs represent unadjusted quoted prices for identical instruments exchanged in active markets. The fair values of publicly traded equity securities, highly liquid cash management funds and short-term U.S. Government securities are based on published quotes in active markets.

Level 2— Inputs include directly or indirectly observable inputs (other than Level 1 inputs) such as quoted prices for similar financial instruments exchanged in active markets, quoted prices for identical or similar financial instruments exchanged in inactive markets and other market observable inputs. The fair value of the vast majority of the Company's investments in fixed maturity securities, along with most derivative contracts are priced based on information provided by independent pricing service providers, while much of the remainder are based primarily on non-binding third party broker-dealer quotes that are prepared using Level 2 inputs. Where third party broker-dealer quotes are used, typically at least one quote is obtained from a broker-dealer with particular expertise in the instrument being priced. Certain common stock investments, which are measured at fair value using the NAV as a practical expedient, have been excluded.

Level 3— Inputs include unobservable inputs used in the measurement of financial instruments. Management is required to use its own assumptions regarding unobservable inputs, as there is little, if any, market activity in these instruments or related observable inputs that can be corroborated at the measurement date. Certain cost-method partnership investments, which are measured at fair value using the NAV practical expedient, have been excluded. Investments for which NAV is only a component of the fair value measurement continue to be included.

The following table presents the Company's investments measured at fair value on a recurring basis as of September 30, 2022 and December 31, 2021 classified by the valuation hierarchy discussed previously:

| | | | | Fai | r Valu | e Measureme | nt Usir | |
|---|----------|-----------|----|---------|----------|-------------------------|----------|--------------------|
| (In thousands) | | Total (a) | | Level 1 | | Level 2 | | Level 3 |
| September 30, 2022 | | | | | | | | |
| Fair value option securities: | | | | | | | | |
| Fixed maturity securities: | | | | | | | | |
| U.S. government debt | \$ | 963,552 | | | \$ | 963,552 | | |
| State and local government debt | | 5,069 | | | | 5,069 | | |
| Foreign government debt | | 14,660 | | | | 14,660 | | |
| Corporate debt | | 17,446 | | | | 15,397 | \$ | 2,049 |
| Total fixed maturity securities | | 1,000,727 | | | | 998,678 | | 2,049 |
| Equity securities (b) | | 403,574 | \$ | 335,873 | | 18,006 | | 18,700 |
| Short-term investments | | 3,996 | | 3,996 | | | | |
| Mortgage loans | | 163,663 | | | | | | 163,663 |
| Other investments – cost-method partnerships (a) (b) | | 42,061 | | | | | | |
| Other investments – affiliate corporate loans (a) | | 14,188 | | | | | | 14,188 |
| Other investments – contingent consideration | | , | | | | | | 2 |
| receivable (a) | | 16,991 | | | | | | 16,99 [,] |
| Total fair value option investments | \$ | 1,645,200 | \$ | 339,869 | \$ | 1,016,684 | \$ | 215,59 |
| Desire the second | | | | | | | | |
| Derivatives: | • | 0.444 | | | | | • | 0.44 |
| Equity warrants | \$ | 3,414 | | | | | \$ | 3,414 |
| CPI-linked derivatives | | 11 | | | • | 4 700 | | 11 |
| Foreign exchange forwards | ^ | 1,768 | | | \$ | 1,768 | • | 0.40 |
| Total derivative assets | \$ | 5,193 | | | \$ | 1,768 | \$ | 3,42 |
| | | | | Fai | r Valu | e Measureme | nt Llein | a |
| (In thousands) | | Total | | Level 1 | i valu | Level 2 | | Level 3 |
| December 31, 2021 | | | | | | | | |
| Fair value option securities: | | | | | | | | |
| Fixed maturity securities: | | | | | | | | |
| U.S. government debt | \$ | 859,036 | | | \$ | 859,036 | | |
| State and local government debt | Ŧ | 10,500 | | | Ŧ | 10,500 | | |
| Foreign government debt | | 13,598 | | | | 13,598 | | |
| Corporate debt | | 14,403 | | | | 6,320 | \$ | 8,083 |
| Total fixed maturity securities | | 897,537 | | | | 889,454 | Ŧ | 8,083 |
| Equity securities (b) | | 348,776 | \$ | 271,590 | | 18,335 | | 23,642 |
| Short-term investments | | 188,687 | Ψ | 188,687 | | 10,000 | | 20,042 |
| Mortgage loans | | 79,337 | | 100,007 | | | | 79,337 |
| Other investments – cost-method partnerships (a) (b) | | 42,598 | | | | | | 10,001 |
| Other investments – affiliate corporate loans (a) | | 10,209 | | | | | | 10,209 |
| Other investments – contingent consideration | | 10,203 | | | | | | 10,203 |
| receivable (a) | | 18,683 | | | | | | 18,683 |
| Total fair value option investments | \$ | 1,585,827 | \$ | 460,277 | \$ | 907,789 | \$ | 139,954 |
| | Ŧ | , , | r | ,= | ŕ | , | r | |
| Derivatives: | | | | | | | | |
| Equity warrants | \$ | 3,189 | | | | | \$ | 3,189 |
| CPI-linked derivatives | | 25 | | | | | | 25 |
| | | 3,214 | | | | | | 3,214 |
| | | | | | | | | |
| Foreign exchange forwards | | (380) | | | \$ | (380) | | |
| Total derivative assets Foreign exchange forwards Total derivative liabilities Net derivatives | \$ | | | | \$ \$ | (380) (380) (380) | \$ | 3,214 |

(a) The fair value amounts presented in the "Total" column are intended to permit reconciliation of the fair value hierarchy to the amounts presented in the Consolidated Balance Sheets. Cost-method partnerships, affiliate corporate loans and contingent consideration receivable are part of the composition of other investments in the Consolidated Balance Sheets. See Note 2 for the full composition of investments recorded under other investments.

(b) As of September 30, 2022 and December 31, 2021, certain common stock investments with a fair value of \$31.0 million and \$35.2 million, respectively, and cost-method partnerships with a fair value of \$42.1 million and \$42.6 million, respectively, are measured using NAV as a practical expedient and not required to be classified in the fair value hierarchy.

The following table presents changes in the Company's Level 3 fixed maturity and equity securities, mortgage loans, affiliate corporate loans, contingent consideration receivable and derivatives measured at fair value on a recurring basis:

| (In thousands) | Corporate Debt | Equity Securities (a) | Mortgage Loans | Affiliate Corporate Loans | Contingent Consideration Receivable | Derivatives |
|---------------------------------------|-------------------|--------------------------|-------------------|---------------------------------|---|-------------|
| Balance as of June 30, 2022 | \$ 2,065 | \$ 20,027 | \$ 117,935 | \$ 14,719 | \$ 17,884 | \$ 2,415 |
| Purchases | | | 45,911 | | | |
| Sales | | | (227) | | (595) | |
| Realized and unrealized gains/losses | | | | | | |
| included in: | | | | | | |
| Net investments income – accretion of | | | | | | |
| discounts | | | 44 | | | |
| Net realized losses on investments | | | | | (19) | |
| Change in net unrealized gains/losses | | | | | | |
| on fair value option investments | (16) | (1,327) | | (531) | (279) | |
| Net gains on derivatives | | | | | | 1,010 |
| Balance as of September 30, 2022 | \$ 2,049 | \$ 18,700 | \$ 163,663 | \$ 14,188 | \$ 16,991 | \$ 3,425 |
| Balance as of December 31, 2021 | \$ 8,083 | \$ 23,642 | \$ 79,337 | \$ 10,209 | \$ 18,683 | \$ 3,214 |
| Purchases | | 4,167 | 86,235 | 5,000 | , | 4,125 |
| Sales | (10,335) | (5,548) | (2,042) | , | (2,095) | (3,532) |
| Realized and unrealized gains/losses | (,) | (0,000) | (_, - , - , | | (_,) | (-,) |
| included in: | | | | | | |
| Net investments income – accretion of | | | | | | |
| discounts | | | 133 | | | |
| Net realized gains (losses) on | | | | | | |
| investments | 5,523 | 1,386 | | | (7) | 240 |
| Change in net unrealized gains/losses | | | | | . , | |
| on fair value option investments | (1,222) | (4,947) | | (1,021) | 410 | |
| Net losses on derivatives | | | | - | | (622) |
| Balance as of September 30, 2022 | \$ 2,049 | \$ 18,700 | \$ 163,663 | \$ 14,188 | \$ 16,991 | \$ 3,425 |

| (In thousands) | | Corporate Debt | Equity Securities (a) | | Mortgage Loans | | Affiliate Corporate Loans | | Contingent Consideration Receivable | | Derivatives |
|---|----|-------------------|--------------------------|----|-------------------|----|---------------------------------|----|---|----|-------------|
| Balance as of June 30, 2021 | \$ | 9,405 | \$ 17,820 | \$ | 34,281 | \$ | 10,315 | | | \$ | 3,496 |
| Purchases | | | 5,000 | | 12,835 | | | \$ | 18,863 | | |
| Sales Realized and unrealized gains/losses included in: | | | | | (10,000) | | | | | | |
| Net investments income – accretion of | | | | | | | | | | | |
| discounts | | | | | 96 | | | | | | |
| Net realized gains on investments | | | | | 113 | | | | | | |
| Change in net unrealized gains/losses on fair value option investments Net gains on derivatives | | (617) | (533) | | | | (400) | | 216 | | 321 |
| | \$ | 8,788 | 22,287 | \$ | 37,325 | \$ | 9,915 | \$ | 19,079 | \$ | |
| Balance as of September 30, 2021 | Ф | 0,700 | 22,201 | φ | 37,323 | φ | 9,915 | Ф | 19,079 | Ф | 3,817 |
| Balance as of December 31, 2020 | \$ | 6,974 | \$ 17,639 | \$ | 18,824 | \$ | 18,065 | | | \$ | 234 |
| Purchases | | | 5,000 | | 28,141 | | 1,133 | \$ | 18,863 | | 133 |
| Sales Realized and unrealized gains/losses included in: | | | | | (10,000) | | (9,289) | | | | |
| Net investments income – accretion of | | | | | | | | | | | |
| discounts | | | | | 247 | | | | | | |
| Net realized gains on investments | | | | | 113 | | 780 | | | | |
| Change in net unrealized gains/losses on fair value option investments | | 1,814 | (352) | | | | (774) | | 216 | | |
| Net gains on derivatives | | | | | | | | | | | 3,450 |
| Balance as of September 30, 2021 | \$ | 8,788 | \$ 22,287 | \$ | 37,325 | \$ | 9,915 | \$ | 19,079 | \$ | 3,817 |

(a) Change in unrealized gains/losses for equity securities include change in fair value and foreign currency fluctuation.

Note 5. Related Party Transactions

Investments

Management of all of the Company's investments is centralized at Fairfax through investment management agreements entered into in 2010. The parties to these agreements are Zenith National's insurance subsidiaries, Fairfax and Hamblin Watsa Investment Counsel, Ltd. ("HWIC"), an affiliate of Fairfax and the Company. Investment management expenses incurred under these agreements in the three and nine months ended September 30, 2022, were \$1.2 million and \$3.8 million, respectively, compared to \$1.3 million and \$3.7 million in the three and nine months ended September 30, 2021, respectively.

The Company owns fixed maturity securities, common stock, preferred stock, corporate loans and equity warrants issued by public and private companies and invests in limited partnerships which are affiliates of Fairfax and the Company (including but not limited to investments described in the following paragraphs). Affiliated common stock investments are recorded using the equity-method of accounting, unless the fair value option is elected. The Company's share of an equity-method investee's net income (loss) and net realized gains (losses) from sales and share dilutions are recorded in net investment income (loss) and net realized gains (losses) from investments, respectively, in the Consolidated Statements of Comprehensive Income (Loss). The Company's share of an equity-method investee's other changes in equity and net unrealized gains (losses) on foreign currency translation adjustments are recorded in the change in unrealized gains/losses on investments and change in unrealized foreign currency translation adjustments, respectively, in other comprehensive income (loss).

The Company's affiliated investments as of September 30, 2022 and December 31, 2021 were as follows:

| (In thousands) | : | September 30, 2022 | December 31, 2021 |
|--|----|-----------------------|----------------------|
| Equity securities, at fair value | \$ | 132,501 | \$ 94,473 |
| Other investments: | | , | , |
| Equity-method common stock | | 88,179 | 84,174 |
| Partnerships, at fair value | | 8,230 | 8,704 |
| Affiliate corporate loans, at fair value | | 14,188 | 10,209 |
| Equity warrants, at fair value | | 3,082 | 3,189 |
| Total | \$ | 246,180 | \$ 200,749 |

The following table summarizes the impact from the Company's affiliated investments on various components of total comprehensive income:

| | Three M Septe | | Nine Mo Septe | | |
|--|------------------|--------------|------------------|----|---------|
| _(In thousands) | 2022 | 2021 | 2022 | | 2021 |
| Included in net income: | | | | | |
| Net investment income | \$ 585 | \$ 1,671 | \$ 3,435 | \$ | 2,096 |
| Net realized gain (loss) on investments | (1,605) | 20,320 | (5,630) | | 43,925 |
| Change in net unrealized gains/losses on fair value option investments | (2,811) | 18 | (18,906) | | 16,003 |
| Net gains (losses) on derivatives | 1,339 | | (106) | | -, |
| Included in other comprehensive loss: | | | () | | |
| Change in unrealized gains/losses on investments, before tax | 202 | (521) | (476) | | 1,657 |
| Change in unrealized foreign currency translation | | | | | |
| adjustments, before tax | (1,873) | (253) | (1,111) | | (2,847) |
| Total | \$ (4,163) | \$ 21,235 | \$ (22,794) | \$ | 60,834 |

The Company owns a fair value investment in the common stock of Recipe, an affiliate of Fairfax and the Company. As of September 30, 2022 and December 31, 2021, the carrying value of the Company's fair value option investment in Recipe was \$8.9 million and \$8.3 million, respectively. On October 28, 2022, Fairfax, through its subsidiaries including the Company, acquired all of the multiple voting shares and subordinate voting shares in the capital of Recipe, other than those shares owned by Fairfax and its affiliates, at a cash purchase price of Cdn\$20.73 per share. The transaction was formally approved at a special meeting of shareholders of Recipe held on October 21, 2022, where 99.87% of all shareholders excluding Fairfax and Cara Holdings Limited voted in favor of the transaction. Court approval of the transaction was obtained on October 25, 2022, and the transaction closed on October 28, 2022. The transaction increased Fairfax's equity ownership in Recipe from 39.4% at September 30, 2022 to approximately 84%, and Recipe was subsequently de-listed from the TSX. The Company's share of this additional investment in Recipe in October 2022 was Cdn\$11.0 million. The Company continues to account for its affiliated common stock investment in Recipe using the fair value option.

The Company owns a fair value option investment in the common stock of Stelco Holdings Inc.("Stelco"), a Canadian publicly traded company. In August 2022, Stelco repurchased 5.1 million of its outstanding common shares under its substantial issuer bid which resulted in the loss of a certain right held by another investor and Fairfax's ownership interest in Stelco increasing to 20.5%. Accordingly, Stelco became an affiliate of Fairfax and the Company and Fairfax commenced applying the equity-method of accounting to its interest in Stelco. The Company continues to account for its affiliated common stock investment in Stelco using the fair value option. As of September 30, 2022, and December 31, 2021, the carrying value of the Company's investment in Stelco was \$43.2 million and \$56.1 million, respectively.

In July 2022, Fairfax through its subsidiaries, including the Company, increased its interest in Grivalia Hospitality S.A. ("GH"), an affiliate of Fairfax and the Company, to 78.4% from 33.5% by acquiring additional common stock shares for cash. The Company initially invested \$7.1 million in GH common stock in July 2022, and accounts for its affiliated common stock investment in GH using the equity-method of accounting. As of September 30, 2022, the carrying value of the Company's investment in GH common stock was \$7.1 million.

In March 2022, the Company acquired 0.5 million of certain common stock warrants from Wentworth Insurance Company, an affiliate of Fairfax and the Company, for \$3.3 million. The warrants had an exercise price of Cdn\$15 per share and an expiration date of April 26, 2022. The Company also owned shares of the preferred stock of the same issuer as these warrants. In April 2022, Fairfax through its subsidiaries, including the Company, exercised the warrants in exchange for the common stock, and surrendered all of its preferred stock, for cancelation, to the issuer as payment.

In February 2022, Fairfax through its subsidiaries, including the Company, invested in a \$45 million shortterm note issued by Access LNG Tema SCS ("Access LNG"), a Luxemburg limited partnership and an indirect investment of Helios, an affiliate of Fairfax and the Company. The note bears a 14% annual interest rate and has an initial term to maturity of nine months, which can be extended for an additional three months at the option of the issuer. The Company invested \$5.0 million in the Access LNG note and recorded this investment as an Affiliate Corporate Loan in Other Assets. As of September 30, 2022, the carrying value of the Company's investment in Access LNG's affiliate corporate loan was \$5.0 million.

The Company owns investments in the common stock, preferred stock, and equity warrants of Atlas, an affiliate of Fairfax and the Company, for which the Company elected the fair value option. As of September 30, 2022, and December 31, 2021, the carrying value of the Company's investments in Atlas preferred stock was \$9.1 million and \$10.0 million, respectively; in Atlas common stock was \$40.3 million and \$40.9 million, respectively; and in Atlas warrants was \$3.1 million and \$3.2 million, respectively.

In February 2020, Seaspan Corporation ("Seaspan") completed a holding company reorganization to create Atlas, whereby Atlas became the parent of Seaspan (the "Reorganization"). Certain Seaspan debentures were exchanged for Atlas preferred stock and Atlas warrants in the second quarter of 2021 and certain other Seaspan debentures were redeemed in the third quarter of 2021. The Company exchanged \$10.0 million par value (fair value of \$10.1 million) of its Seaspan bonds due in 2027 for 0.4 million shares of Atlas preferred stock (cost basis of \$10.0 million) and 33,000 shares of Atlas warrants (cost basis of \$0.1 million) and recorded a realized gain of \$0.1 million on the conversion.

In April 2021, Fairfax signed an amendment agreement in relation to the original sale of AB to Atlas, both affiliates of Fairfax and the Company, to potentially compensate Atlas for certain amounts and balances acquired in the transaction ("AB Indemnity"). In the nine months ended September 30, 2022, and 2021, the Company recorded realized losses of \$5.8 million and \$10.9 million, respectively, for its share of realized losses related to the AB Indemnity and additional foreign exchange realized losses. As of September 30, 2022 and December 31, 2021, the carrying value of the Company's outstanding AB Indemnity liability was \$14.9 million and \$11.7 million, respectively. As part of the agreement, Atlas also issued warrants to Fairfax and the Company with an exercise price of \$13 per share and at no cost, expiring in April 2026. The Company received 0.6 million shares of these Atlas warrants.

On October 31, 2022 a consortium composed of Fairfax and certain other shareholders and directors of Atlas (collectively, the "Consortium"), signed a definitive agreement to acquire all of the outstanding common shares of Atlas, other than those shares owned by the Consortium, at a cash purchase price of \$15.50, plus payment of all ordinary course quarterly dividends up until closing of the transaction. Pursuant to the transaction, Fairfax would transfer its approximate 45% interest in Atlas, inclusive of Fairfax's interest upon eventual exercise of its holdings in Atlas equity warrants, into an entity formed by the Consortium, and is not obligated to purchase any additional interest not already owned by the Consortium. The other members of the Consortium have committed to fully fund the cash component of the transaction, and Fairfax would continue its ownership in Atlas as part of the Consortium. Closing of the transaction is expected to be completed in the first half of 2023, and is subject to receipt of shareholder and regulatory approvals and certain other customary closing conditions.

The Company owns a fair value option investment in the limited partnership of Transportation Recovery Fund ("TRF"). Fairfax, through its subsidiaries including the Company, has been a limited partner investor since 2013. In April 2021, a Fairfax representative signed an agreement to provide services to a new sub-advisor and participate in both the management group and the investment committee of TRF. Fairfax concluded that this appointment resulted in significant influence over the operations of TRF. The Company continues to account for its investment in TRF using the fair value option, with fair value equal to NAV and no impact to the carrying value of TRF; however, TRF is now considered an affiliate of Fairfax and the Company. As of September 30, 2022, and December 31, 2021, the carrying value of the Company's investment in TRF was \$8.2 million and \$8.7 million, respectively.

The Company owns an equity-method investment in the common stock of FE, a majority-owned subsidiary of Fairfax and an affiliate of the Company. In March 2021, FE completed its IPO, issuing 7.4 million common shares at Cdn\$17.00 per share. The common stock shares began trading on the TSX under the ticker symbol: FDGE. All outstanding FE convertible debentures held by Fairfax through its subsidiaries, including the Company ("FE affiliate loans") were exchanged for 114.6 million pre-IPO common shares. All FE common shares outstanding prior to the IPO were then consolidated into fewer shares through a 7 for 1 reverse stock split. In connection with the conversion of FE's affiliate loans, the Company recorded a realized gain of \$0.8 million and increased the cost basis of its investment in FE common stock by \$9.3 million, representing additional shares received, at fair value equal to the IPO price. In September 2022 and December 2021, the Company recorded other-than-temporary impairments of \$1.3 million and \$14.5 million, respectively, as a result of the extent and duration that the fair value of FE's common stock had been below its carrying value.

As of September 30, 2022, and December 31, 2021, the carrying value of the Company's equity-method investment in FE common stock was \$0.7 million and \$3.7 million, respectively.

The Company owns an equity-method investment in the common stock of Boat Rocker, a majority-owned subsidiary of Fairfax and an affiliate of the Company. In March 2021, Boat Rocker completed its IPO, issuing 18.9 million common stock shares at Cdn\$9.00 per share. The common stock shares began trading on the TSX under the ticker symbol: BRMI. Prior to the IPO, Boat Rocker effected a 1.6016 for 1 stock split on its common shares outstanding, resulting in an increase in shares issued and outstanding. As of September 30, 2022, and December 31, 2021, the carrying value of the Company's equity-method investment in Boat Rocker common stock was \$17.3 million and \$18.6 million, respectively.

Other

In October 2022, Zenith National paid a \$29.0 million ordinary dividend in cash to affiliates of Fairfax and the Company.

The Company entered into reinsurance agreements with various subsidiaries of Allied effective May 1, 2021, under which Allied cedes a portion of its global professional and medical liability business under the quota share and excess of loss reinsurance contracts on a risk-attaching basis. These reinsurance agreements were renewed effective May 1, 2022. Effective July 1, 2022, the Company entered into a risk attaching quota share agreement under which Allied cedes a portion of its Cyber business. Total estimated premium assumed by the Company for these agreements is expected to be earned over the 24-month period following the effective dates of the agreements.

The following table summarizes the impact from these agreements on various components of the balance sheet:

| (In thousands) | | September 30, 2022 | December 31, 2021 |
|--|----|--------------------|----------------------|
| Assets: | | | |
| Premiums receivable | \$ | 9,836 | \$ 6,583 |
| Deferred policy acquisition costs | | 5,479 | 3,751 |
| Liabilities: | | | |
| Unpaid losses and loss adjustment expenses | | 15,578 | 3,632 |
| Unearned premiums | | 15,422 | 11,130 |

The following table summarizes the impact from these agreements on various components of net income:

| (In thousands) | Three Mo Septer | | Nine Months Ended September 30, | | | | |
|--|--------------------|----|------------------------------------|--------------|----|-------|--|
| | 2022 | | 2021 | 2022 | | 2021 | |
| Revenues: | | | | | | | |
| Net premium earned | \$ 7,534 | \$ | 2,323 | \$ 18,733 | \$ | 2,323 | |
| Expenses: | | | | | | | |
| Loss and loss adjustment expenses incurred | 5,242 | | 1,504 | 12,236 | | 1,504 | |
| Policy acquisition costs | 2,625 | | 783 | 6,409 | | 783 | |

The Company continues to be a party to various ceded reinsurance treaties with affiliates of Fairfax that were entered into in the ordinary course of business, primarily excess of loss reinsurance agreements with Odyssey Re for 2010 through 2022. As of September 30, 2022, and December 31, 2021, the Company recorded net payables for reinsurance of \$0.6 million and \$0.1 million, respectively, related to the reinsurance transactions with affiliates of Fairfax. In the three and nine months ended September 30, 2022, the Company

recorded \$1.4 million and \$3.0 million, respectively, of ceded premium earned, compared to \$1.0 million and \$2.7 million in the three and nine months ended September 30, 2021, respectively.

In the nine months ended September 30, 2022 and 2021, Zenith National paid Fairfax \$9.3 million and \$4.8 million, respectively, for the cost of the open market purchases made by Fairfax on behalf of Zenith National of Fairfax Subordinate Voting Shares granted to certain officers under the Restricted Stock Plan.

The Company is party to Master Administrative Services Agreements with various affiliates of Fairfax and the Company. Under the agreements, the affiliated parties provide and receive administration services such as accounting, underwriting, claims, reinsurance, preparation of regulatory reports, and actuarial services. The Company provides claims administration services to Seneca Insurance Company, Inc. ("Seneca") and to RiverStone Group LLC and affiliates ("RiverStone"), both affiliates of Fairfax and the Company. Claims administration for RiverStone started in 2013 primarily for TIG Insurance Company workers' compensation claims, and starting in December 2021, includes certain Crum & Forster Holdings Corp. workers' compensation claims assumed by RiverStone. In the three and nine months ended September 30, 2022 and 2021, service fee income recorded in the Consolidated Statements of Comprehensive Income (Loss), for RiverStone was \$1.8 million and \$4.5 million and \$1.3 million and \$3.6 million, respectively, and for Seneca was \$33,000 and \$85,000 and \$40,000 and \$119,000, respectively. As of September 30, 2022 and December 31, 2021, the Company recorded a net liability of \$3.5 million and \$2.6 million, respectively, to RiverStone comprised of a loss fund held for RiverStone claims of \$4.1 million and \$3.3 million, respectively. As of September 30, 2022 and December 30, 2022 and December 31, 2021, the loss fund held for Seneca claims was \$0.4 million.

Note 6. Reinsurance Recoverable

Amounts recoverable for paid and unpaid losses from reinsurers as of September 30, 2022 and December 31, 2021 and their respective A.M. Best ratings were as follows:

| (In thousands) | September 30, 2022 (a) | December 31, 2021 (a) | A.M. Best Rating (b) | A.M. Best Rating Date |
|---------------------------------------|---------------------------|--------------------------|-------------------------|--------------------------|
| General Reinsurance Corp. | \$ 21,337 | \$ 23,175 | A++ | 04/2022 |
| Transatlantic Reinsurance Company | 10,774 | 9,885 | A+ | 10/2022 |
| Hannover Rueck SE | 4,613 | 2,670 | A+ | 01/2022 |
| Partner Reinsurance Company | 4,431 | 3,595 | A+ | 05/2022 |
| Zenith Insurance 2019 AG IC 1 LLC (c) | 1,652 | 2,039 | NR | |
| Factory Mutual Insurance Company | 1,287 | 1,039 | A+ | 01/2022 |
| All others (d) | 5,543 | 5,451 | | |
| Total | \$ 49,637 | \$ 47,854 | | |

(a) Under insurance regulations in California, reinsurers placed securities on deposit equal to the California component of the Company's ceded workers' compensation loss reserves.

(b) A.M. Best, in assigning ratings, is primarily concerned with the ability of insurance and reinsurance companies to pay the claims of policyholders. In the A.M. Best ratings scheme, ratings of B+ to A++ are considered "Secure" and ratings of B and below are considered "Vulnerable." NR means A.M. Best does not rate the reinsurer.

- (c) Group captive sponsored by the Company, effective January 1, 2020.
- (d) No individual reinsurer in excess of \$1.2 million as of September 30, 2022 and December 31, 2021.

2022 Reinsurance Ceded Workers' Compensation Coverage

The Company maintains excess of loss catastrophe reinsurance that provides protection for losses up to \$150 million for losses including catastrophe losses arising out of earthquakes and acts of terrorism including nuclear, biological and chemical attacks. For the agriculture business, the Company retains the first \$10 million of each loss arising from industrial accidents and the first \$20 million of each loss arising out of earthquakes and acts of terrorism. For all other business classes, the Company retains the first \$20 million of each loss. In April 2022, the Company entered into a new multi-cedant reinsurance contract for the \$50 million in excess of \$100 million layer, shared with other Fairfax affiliates.

2022 Reinsurance Ceded Agribusiness P&C Coverage

From January 1, 2022 through March 31, 2022, the Company maintained excess of loss per risk and catastrophe reinsurance on its Agribusiness P&C property lines of business that provides protection for losses up to \$25 million and \$20 million, respectively. In April 2022, the Company increased the catastrophe reinsurance coverage to \$25 million. The Company retains the first \$3.5 million for each per risk loss and \$5.0 million for catastrophe loss.

From January 1, 2022 through June 30, 2022, the Company participated in a quota share reinsurance agreement for the umbrella line of business. Under this quota share agreement, the Company retains 50% of the first \$1 million and 10% in excess of \$1 million up to \$10 million on any one policy, any one claim or any one occurrence. On July 1, 2022, the terms of the quota share reinsurance agreement for the umbrella line of business changed and the Company now retains 27.5% of the first dollar up to \$10 million on any one policy, any one policy, any one claim or any one occurrence. The Company also participates in a quota share reinsurance agreement for the equipment breakdown lines of business. Under the equipment breakdown quota share agreement, the Company cedes 100% of losses up to \$100 million.

2021 Reinsurance Ceded Workers' Compensation Coverage

The Company maintained excess of loss catastrophe reinsurance that provides protection for losses up to \$150 million for losses including catastrophe losses arising out of earthquakes and acts of terrorism including nuclear, biological and chemical attacks. For the agriculture business, the Company retains the first \$10 million of each loss arising from industrial accidents and the first \$20 million of each loss arising out of earthquakes and acts of terrorism. For all other business classes, the Company retains the first \$20 million of each loss.

2021 Reinsurance Ceded Agribusiness P&C Coverage

The Company maintained excess of loss per risk and catastrophe reinsurance on its Agribusiness P&C property lines of business that provides protection for losses up to \$25 million and \$20 million, respectively. The Company retains the first \$3.5 million for each per risk loss and \$5.0 million for catastrophe loss.

The Company also participates in quota share reinsurance agreements for the umbrella and equipment breakdown lines of business. Under the umbrella quota share agreement, the Company retains 50% on the first \$1 million and 10% in excess of \$1 million up to \$10 million on any one policy, any one claim or any one occurrence. Under the equipment breakdown quota share agreement, the Company cedes 100% of losses up to \$100 million.

Note 7. Unpaid Losses and Loss Adjustment Expenses

| (In thousands) | September 30, 2022 | September 30, 2021 |
|--|-----------------------|-----------------------|
| Beginning of period, net of reinsurance | \$ 1,003,800 | \$ 1,021,329 |
| Incurred claims: | | |
| Current accident year | 332,164 | 323,266 |
| Prior accident years | (34,349) | (46,162) |
| Total incurred claims | 297,815 | 277,104 |
| Payments: | | |
| Current accident year | (87,642) | (79,708) |
| Prior accident years | (204,746) | (195,613) |
| Total payments | (292,388) | (275,321) |
| End of period, net of reinsurance | 1,009,227 | 1,023,112 |
| Receivable from reinsurers for unpaid losses | 46,417 | 44,294 |
| End of period, gross of reinsurance | \$ 1,055,644 | \$ 1,067,406 |

The following table represents a reconciliation of changes in the liability for unpaid losses and loss adjustment expenses:

Note 8. Other Comprehensive Loss

Other comprehensive loss is comprised of changes in unrealized gains/losses on investments and foreign currency translation adjustments. The following table summarizes the components of the Company's other comprehensive loss:

| | | Income Tax | After- |
|---|---------------|---------------|---------------|
| (In thousands) | Pre-Tax | Effect | Tax |
| Three Months Ended September 30, 2022 | | | |
| Change in unrealized gains/losses on investments | \$ 202 | \$ 43 | \$ 159 |
| Change in unrealized foreign currency translation adjustments | (1,873) | (394) | (1,479) |
| Total other comprehensive loss | \$ (1,671) | \$ (351) | \$ (1,320) |
| Nine Months Ended September 30, 2022 | | | |
| Change in unrealized gains/losses on investments | \$ (476) | \$ (99) | \$ (377) |
| Change in unrealized foreign currency translation adjustments | (1,111) | (234) | (877) |
| Total other comprehensive loss | \$ (1,587) | \$ (333) | \$ (1,254) |
| Three Months Ended September 30, 2021 | | | |
| Change in unrealized gains/losses on investments | \$ (521) | \$ (109) | \$ (412) |
| Net unrealized foreign currency translation adjustment | (156) | (33) | (123) |
| Less: reclassification adjustment for net realized foreign exchange | . , | . , | . , |
| gains included in net income | (97) | (20) | (77) |
| Change in unrealized foreign currency translation adjustments | (253) | (53) | (200) |
| Total other comprehensive loss | \$ (774) | \$ (162) | \$ (612) |
| Nine Months Ended September 30, 2021 | | | |
| Change in unrealized gains/losses on investments | \$ 1,657 | \$ 348 | \$ 1,309 |
| Net unrealized foreign currency translation adjustment | (2,750) | (578) | (2,172) |
| Less: reclassification adjustment for net realized foreign exchange | . , | . , | . , |
| gains included in net income | (97) | (20) | (77) |
| Change in unrealized foreign currency translation adjustments | (2,847) | (598) | (2,249) |
| Total other comprehensive loss | \$ (1,190) | \$ (250) | \$ (940) |

The following table summarizes the net unrealized losses on investments and foreign currency translation adjustment recognized in accumulated other comprehensive loss:

| (In thousands) | September 30, 2022 | December 31, 2021 |
|---|-----------------------|----------------------|
| Net unrealized loss on investments, before tax | \$ (8,159) | \$ (7,683) |
| Deferred tax benefit | (1,713) | (1,614) |
| Net unrealized loss on investments, after tax | (6,446) | (6,069) |
| Net unrealized loss on foreign currency translation adjustments, before tax | (4,884) | (3,773) |
| Deferred tax benefit | (1,026) | (792) |
| Net unrealized loss on foreign currency translation adjustments, after tax | (3,858) | (2,981) |
| Total accumulated other comprehensive loss | \$ (10,304) | \$ (9,050) |

Note 9. Stock-Based Compensation

The following table provides information about the Fairfax Subordinate Voting Shares under the Restricted Stock Plan:

| | Number of Shares |
|---|------------------|
| Authorized for purchases and grants at plan inception in 2010 | 200,000 |
| Additional authorization in 2020 | 300,000 |
| Total authorized for purchases and grants | 500,000 |
| Purchased and restricted | (66,679) |
| Vested | (84,138) |
| Purchased and available for future grants | (11,869) |
| Available for future purchases as of September 30, 2022 | 337,314 |

The following represents open market purchases of Fairfax Subordinate Voting Shares under the Restricted Stock Plan which also resulted in charges to the Company's Stockholders' equity:

| (Dollars in thousands, except share data) | Number of Shares | Weighted Average Purchase Price Per Share | Total Purchase Price |
|---|---------------------|--|----------------------------|
| Purchased through December 31, 2019 | 118,352 | \$ 441.40 | \$ 52,240 |
| Purchased in 2020 | 11,518 | 381.37 | 4,393 |
| Purchased in 2021 | 14,526 | 441.18 | 6,409 |
| Purchased in 2022 | 18,290 | 509.21 | 9,313 |
| Total purchased since plan inception | 162,686 | 444.75 | \$ 72,355 |

Changes in the restricted shares outstanding were as follows:

| (Dollars in thousands, except share data) | Number of Shares | Weighted Average Grant Date Fair Value Per Share | Grant Date Fair Value |
|--|---------------------|---|-----------------------------|
| Restricted Shares at December 31, 2020 | 57,601 | \$ 463.34 | \$ 26,690 |
| Granted during 2021 | 22,496 | 405.50 | 9,122 |
| Forfeited during 2021 | (1,224) | 466.47 | (571) |
| Vested during 2021 | (8,933) | 449.52 | (4,016) |
| Restricted Shares at December 31, 2021 | 69,940 | 446.45 | 31,225 |
| Granted during 2022 | 11,715 | 495.34 | 5,803 |
| Forfeited during 2022 | (1,835) | 448.82 | (824) |
| Vested during 2022 | (13,141) | 448.91 | (5,899) |
| Restricted Shares as of September 30, 2022 | 66,679 | 454.49 | \$ 30,305 |

In the three and nine months ended September 30, 2022, stock-based compensation expense before tax was \$2.0 million and \$6.2 million, respectively, compared to \$1.3 million and \$4.0 million for the same periods in 2021.

As of September 30, 2022 and December 31, 2021, unrecognized compensation expense before tax under the Restricted Stock Plan was \$16.0 million and \$17.1 million, respectively.

Note 10. Commitments and Contingencies

The Company is involved in various litigation proceedings that arise in the ordinary course of business. Disputes adjudicated in the workers' compensation administrative systems may be appealed to review boards or civil courts, depending on the issues and local jurisdictions involved. From time to time, plaintiffs also sue the Company on theories falling outside of the exclusive jurisdiction and remedies of the workers' compensation claims adjudication systems. Certain of these legal proceedings seek injunctive relief or substantial monetary damages, including claims for punitive damages, which may not be covered by reinsurance agreements. Historically, the Company has not experienced any material exposure or damages from any of these legal proceedings. In addition, in the opinion of management, after consultation with legal counsel, currently outstanding litigation is either without merit or the ultimate liability, if any, is not expected to have a material adverse effect on the Company's consolidated financial condition, results of operations or cash flows.